ResultsIQ › Latest results › Zydus Lifesciences Limited
Zydus Lifesciences Limited Q2 FY27 earnings call summary
NSE: ZYDUSLIFE · BSE: 532321
Earnings call of 4 Nov 2026, summarised by AI from the filing.
Zydus Q2 FY27 revenue ₹79.1 billion, up 29%, with 24% EBITDA margin; FY27 margin guidance of 24% plus maintained.
Key takeaways
- Margin guidance 24% plus EBITDA margin maintained for FY27, with second-half margin similar as Saroglitazar spend rises.
- US specialty Specialty reached 16% of US revenue, up approximately 550 basis points sequentially, driven by Rolvedon and Sentynl.
- Margin risk Rising Saroglitazar commercial spend and lower-margin wellness mix keep gross margin from reflecting US improvement.
Zydus Lifesciences Limited Q2 FY27 results
As filed: Revenue ₹7,910 cr (+29% year on year), EBITDA ₹1,895 cr (−6% year on year), PAT ₹928 cr (−25% year on year), EBITDA margin 24.0% (−896 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹8,017 cr (+22% year on year), EBITDA ₹1,929 cr (−8% year on year), PAT ₹990 cr (−35% year on year), EBITDA margin 24.1% (−771 bps). Score 25 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 771 bps year on year. Profit fell 26% from last quarter. Share price after the results: −0.1% in 30 days (Nifty 500: −3.3%).
- Q4 FY26: Revenue ₹7,587 cr (+16% year on year), EBITDA ₹2,554 cr (+20% year on year), PAT ₹1,341 cr (+9% year on year), EBITDA margin 33.7% (+110 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin rose 110 bps year on year. Consolidated profit +8% but standalone -39%. Revenue rose ₹1,059 cr on a year ago, more than the ₹994 cr it added the year before. Share price after the results: +8.4% in 30 days (Nifty 500: +3.3%).
- Q3 FY26: Revenue ₹6,865 cr (+30% year on year), EBITDA ₹1,816 cr (+31% year on year), PAT ₹1,023 cr (0% year on year), EBITDA margin 26.5% (+14 bps). Score 63 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 14 bps year on year. Profit fell 17% from last quarter. Share price after the results: +3.8% in 30 days (Nifty 500: −5.9%).
- Q2 FY26: Revenue ₹6,123 cr (+17% year on year), EBITDA ₹2,015 cr (+38% year on year), PAT ₹1,239 cr (+35% year on year), EBITDA margin 32.9% (+499 bps). Score 76 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 499 bps year on year. Revenue fell 7% from last quarter. Profit rose ₹319 cr on a year ago, more than the ₹117 cr it added the year before. Share price after the results: −4.1% in 29 days (Nifty 500: +0.7%).
- Q1 FY26: Revenue ₹6,574 cr (+6% year on year), EBITDA ₹2,089 cr (0% year on year), PAT ₹1,521 cr (+3% year on year), EBITDA margin 31.8% (−179 bps). Score 15 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 179 bps year on year. Consolidated profit +3% but standalone -77%. Revenue rose ₹366 cr on a year ago, against ₹1,068 cr the year before. Share price after the results: +9.2% in 30 days (Nifty 500: +2.1%).
- Q4 FY25: Revenue ₹6,528 cr (+18% year on year), EBITDA ₹2,126 cr (+30% year on year), PAT ₹1,244 cr (+22% year on year), EBITDA margin 32.6% (+310 bps). Score 62 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 310 bps year on year. Consolidated profit 0% but standalone +100%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹994 cr on a year ago, more than the ₹523 cr it added the year before. Share price after the results: +4.3% in 30 days (Nifty 500: −0.4%).
- Q3 FY25: Revenue ₹5,269 cr (+17% year on year), EBITDA ₹1,387 cr (+26% year on year), PAT ₹1,026 cr (+30% year on year), EBITDA margin 26.3% (+184 bps). Score 65 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 184 bps year on year. Profit rose ₹236 cr on a year ago, more than the ₹159 cr it added the year before.
Past price moves after results do not indicate future moves. Not a recommendation.
Zydus Lifesciences Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (4 Nov 2026), Results deck (4 Nov 2026)
- Q1 FY27: Earnings call (11 Aug 2026), Results deck (11 Aug 2026)
- Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
- Q3 FY26: Earnings call (10 Feb 2026), Results deck (9 Feb 2026), Results press release (9 Feb 2026)
- Q2 FY26: Earnings call (6 Nov 2025), Results deck (6 Nov 2025)
- Q1 FY26: Earnings call (12 Aug 2025), Results deck (12 Aug 2025)
- Q4 FY25: Earnings call (20 May 2025), Results deck (20 May 2025)
- Other events: Press release (31 Aug 2026), Strategy deck (23 Aug 2026), Strategy deck (25 Nov 2025), Press release (29 Aug 2025), Strategy deck (24 Jun 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.